Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. knows a thing or two about developing successful liver disease therapies, since it owns the world's top two hepatitis C drugs in terms of sales, and now the company is attempting to dominate another liver disease with the purchase of Nimbus Apollo Inc. for up to $1.2bn.
You may also be interested in...
Finance Watch: Erasca Raises $200m As VC Mega-Rounds Continue
Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.
Gilead May Have Better Takeover Targets Than Tesaro
Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.
Gilead Data Suggest Role For ACC Inhibition In NASH
With Phase II data showing its ACC inhibitor GS-0976 can significantly reduce hepatic steatosis, Gilead moves a step closer to goal of developing a proprietary combo therapy for NASH.
Need a specific report? 1000+ reports available
Buy Reports